DR TOUX SYRUP

Indications

• Symptomatic relief of allergic rhinoconjunctivitis (hay fever)
• Chronic idiopathic urticaria (hives)

Dosage

Children: For children aged 6 to 12 years, the typical dose is 5 mg once daily for children weighing less than 30 kg, and 10 mg once daily for those weighing 30 kg or more. For children aged 2 to 5 years, 2.5 mg once daily is recommended

Adults: The usual adult dose is 10 mg once daily. In some cases, this can be adjusted based on individual response and tolerability.

Mechanism of action

Cetirizine selectively inhibits the H1 receptor, preventing the action of histamine, which is released during allergic reactions. By blocking these receptors, cetirizine reduces symptoms associated with allergic responses, including itching, sneezing, and runny nose. It also exhibits mild anticholinergic properties, which contribute to its effectiveness in alleviating symptoms.

Pharmacodynamics

Cetirizine has a faster onset of action compared to older antihistamines, providing relief from allergy symptoms within 1 hour of administration. Its effects can last for up to 24 hours, allowing for once-daily dosing. The drug is generally well-tolerated, with sedation being less common than with first-generation antihistamines due to its reduced penetration across the blood-brain barrier.

Pharmacokinetics

Cetirizine is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. It is approximately 93% bound to plasma proteins. The elimination half-life is about 8 hours in healthy adults, but may be prolonged in individuals with renal impairment. Cetirizine is primarily excreted unchanged in the urine, and dose adjustments may be necessary for patients with significant renal dysfunction.

Contra-indications

• Acute porphyrias
• Severe renal impairment

Adverse effects

• Drowsiness
• Headache
• Anxiety
• Increased appetite
• Asthenia
• Diarrhoea
• Dry mouth
• Dyspnoea
• Fever
• Gastritis
• Gastrointestinal discomfort
• Insomnia
• Nasal complaints
• Nausea
• Oral herpes

Interactions

• Other antihistamines (non-sedating)

Precautions

• Drowsiness may occur and affect performance of skilled tasks, such as cycling or driving
• Alcohol should be avoided

Pregnancy

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

Breast-feeding

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

Storage

Store in a cool, dry place away from light.

Formulations

• Cetirizine hydrochloride 10 mg tablets
• Cetirizine hydrochloride 10 mg oral solution

Indications

• Nitrogen supplementation in clinical nutrition
• Management of metabolic alkalosis
• Treatment of certain types of kidney disorders

Dosage

Children: Specific pediatric dosing information is not detailed in the BNF. Refer to the BNF for Children for appropriate dosing based on age and condition.

Adults: Dosage varies based on clinical indication and should be guided by specific treatment protocols. Refer to clinical guidelines for detailed dosing information.

Mechanism of action

Ammonium ions participate in various metabolic pathways, including the biosynthesis of amino acids and nucleotides. It serves as a nitrogen source for organisms, facilitating the synthesis of essential biomolecules. The presence of ammonium can influence pH levels and osmotic balance within cells, thereby affecting cellular functions and enzyme activities.

Pharmacodynamics

Ammonium affects cellular metabolism by acting as a nitrogen donor in the synthesis of organic compounds. Its role in the nitrogen cycle and as a substrate in biochemical pathways allows for the maintenance of cellular functions, including energy production and cellular growth. Alterations in ammonium levels can influence various physiological processes, including neurotransmitter synthesis and energy metabolism.

Pharmacokinetics

Ammonium is readily absorbed and distributed in biological systems. It can be produced endogenously through amino acid metabolism or obtained from dietary sources. The excretion of ammonium primarily occurs through the kidneys, where it is converted to urea for elimination. Ammonium levels are regulated by various mechanisms, including the action of renal tubular cells that either secrete or reabsorb ammonium based on the body's needs.

Indications

• Cough associated with respiratory tract infections
• Acid-base disorders
• Edema management

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines based on age and condition.

Adults: Refer to the BNF for specific adult dosing guidelines as they depend on the indication and clinical context.

Mechanism of action

Ammonium chloride increases acidity by raising hydrogen ion concentrations. It dissociates into ammonium and chloride ions; the ammonium is converted to urea in the liver, releasing hydrogen ions that lower pH. The chloride ions displace bicarbonate in extracellular fluid, leading to acidosis and increased renal excretion of electrolytes and water, resulting in fluid mobilization.

Pharmacodynamics

Ammonium chloride acts as a systemic acidifier, facilitating the excretion of chloride and sodium, while also increasing the acidity of body fluids. The conversion of ammonium to urea in the liver with the release of hydrogen ions contributes to a decrease in blood pH, affecting acid-base balance in the body.

Pharmacokinetics

Ammonium chloride is absorbed from the gastrointestinal tract and metabolized in the liver, where it is converted to urea. The dissociated ions impact renal function, leading to increased excretion of sodium, potassium, and water. The elimination half-life and specific metabolism details are not explicitly defined.

Adverse effects

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Dizziness
• Headache

Interactions

• Antacids may reduce the effectiveness of ammonium chloride
• Potassium-sparing diuretics may increase the risk of hyperkalemia

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolyte levels during prolonged therapy
• Consider potential for acidosis in patients with liver disease

Pregnancy

Ammonium chloride should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider for individualized advice.

Breast-feeding

Ammonium chloride is excreted in breast milk. Use caution and consult a healthcare provider if breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Oral solution
• Powder for oral solution

Indications

• Allergic rhinitis (seasonal and perennial)
• Chronic idiopathic urticaria
• Allergic asthma
• Physical urticaria
• Atopic dermatitis

Dosage

Children: For children aged 6 to 12 years, the usual dose is 5 mg twice daily or 10 mg once daily. For children aged 2 to 5 years, the usual dose is 2.5 mg twice daily or 5 mg once daily

Adults: The usual adult dose is 10 mg once daily, which can be taken with or without food.

Mechanism of action

Cetirizine selectively inhibits peripheral H1 receptors, leading to a reduction in the effects of histamine, a chemical responsible for allergic symptoms. The drug demonstrates negligible anticholinergic and antiserotonergic activity. It has shown to have minimal penetration into the central nervous system, thereby reducing the likelihood of sedation, a common side effect associated with antihistamines.

Pharmacodynamics

Cetirizine exhibits antihistaminic and anti-inflammatory effects that are beneficial in managing allergic conditions. It effectively alleviates symptoms of chronic idiopathic urticaria and both perennial and seasonal allergic rhinitis. Clinical trials have established its efficacy in improving symptoms of allergic respiratory diseases, and it significantly inhibits wheal and flare responses within 20 minutes of administration, with effects lasting for up to 24 hours.

Pharmacokinetics

Cetirizine is well absorbed after oral administration, with peak plasma concentrations typically occurring within 1 hour. It has a long half-life, allowing for once-daily dosing. The drug is primarily eliminated via the kidneys, with a portion being excreted unchanged. Its pharmacokinetic profile demonstrates low potential for significant central nervous system penetration, contributing to its reduced sedation compared to first-generation antihistamines.

Adverse effects

• dry mouth
• drowsiness
• fatigue
• headache
• nausea
• dizziness

Precautions

• Caution in patients with renal impairment
• Caution when driving or operating machinery due to potential drowsiness

Pregnancy

Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult relevant guidelines.

Breast-feeding

Cetirizine is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store below 25°C. Protect from light and moisture. Keep out of reach of children.

Formulations

• tablets
• oral solution
• chewable tablets

Indications

• Cough
• Pseudobulbar affect

Dosage

Children: Refer to the BNF for Children for specific dosing information tailored to paediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the formulation and clinical context.

Mechanism of action

Dextromethorphan acts as a low-affinity uncompetitive antagonist of NMDA receptors and as an agonist at sigma-1 receptors. It also antagonizes α3/β4 nicotinic receptors. The clinical effects are thought to arise from NMDA receptor blockade and serotonin (5-HT) uptake inhibition, which may lead to increased serotonin receptor stimulation. However, the precise mechanisms by which these actions translate into therapeutic effects remain incompletely understood.

Pharmacodynamics

Dextromethorphan is considered an opioid-like molecule with a moderate therapeutic window, indicating that while it is effective at standard doses, higher doses can lead to intoxication. It has a moderate duration of action, making it suitable for use in cough management. Due to its potential for abuse and risk of intoxication, patients are advised to use it cautiously.

Pharmacokinetics

Dextromethorphan is metabolized primarily in the liver through the cytochrome P450 enzyme system, leading to the formation of its active metabolite, dextrorphan. The pharmacokinetics may be influenced by individual variations in metabolic pathways, which can affect the drug's efficacy and safety profile.

Contra-indications

• Hypersensitivity to dextromethorphan or any of its components
• Concurrent use with monoamine oxidase inhibitors (MAOIs)
• Severe respiratory insufficiency or asthma
• Persistent cough due to smoking, emphysema, or chronic bronchitis

Adverse effects

• Dizziness
• Nausea
• Vomiting
• Drowsiness
• Confusion
• Constipation
• Abdominal discomfort
• Euphoria or dysphoria
• Serotonin syndrome (when used with serotonergic drugs)

Interactions

• May interact with MAOIs, leading to serious side effects
• Potential interactions with other CNS depressants, leading to increased sedation
• May enhance the effects of alcohol
• Can interact with medications that affect serotonin levels, increasing the risk of serotonin syndrome

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor use in patients with hepatic impairment
• Caution advised in patients with a history of seizures
• Should not be used in children under 2 years unless directed by a physician

Pregnancy

Dextromethorphan should be used during pregnancy only if clearly needed. Consult a healthcare provider for advice.

Breast-feeding

Dextromethorphan is excreted in breast milk. Caution is advised when administered to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Oral syrup
• Tablets
• Capsules
• Lozenges

Indications

• Malabsorption syndromes
• Crohn's disease
• Cystic fibrosis
• Short bowel syndrome
• Severe food allergies
• Inability to meet nutritional needs through standard diets

Dosage

Children: Refer to specific formulations for dosing, as paediatric dosages depend on the product and the child's nutritional needs.

Adults: Refer to specific formulations for dosing, as adult dosages vary based on the product used and the patient's nutritional requirements.

Mechanism of action

Elemental formulations provide nutrients in their simplest forms, which are readily absorbed in the small intestine. This bypasses complex digestive processes, making them suitable for individuals with compromised digestion or absorption capabilities. The nutrients in these formulations include amino acids, simple carbohydrates, and fatty acids, which can be directly utilized by the body's metabolic pathways.

Pharmacodynamics

Elemental formulations help restore nutritional balance by supplying essential macronutrients and micronutrients needed for metabolic processes. They support growth, maintain energy levels, and promote healing in patients with malabsorption or increased nutritional needs. The bioavailability of nutrients in elemental forms is typically high, allowing for efficient uptake and utilization by the body.

Pharmacokinetics

Following administration, elemental nutrients are absorbed in the gastrointestinal tract, primarily in the jejunum and ileum. The rate of absorption can vary based on the specific formulation and the individual's gastrointestinal health. Once absorbed, these nutrients enter systemic circulation and are transported to various tissues for utilization in metabolic processes. The elimination of unabsorbed nutrients occurs primarily through feces.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach cramps
• Dark stools
• Metallic taste
• Allergic reactions

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for signs of iron overload in patients receiving multiple iron products.
• Assess for the need for supplementation in patients with conditions causing malabsorption.

Pregnancy

Iron is essential during pregnancy, but supplementation should be guided by clinical need and under healthcare supervision.

Breast-feeding

Iron is excreted in breast milk; supplementation may be necessary depending on maternal iron status.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Liquid formulations
• Injectable solutions

Mechanism of action

Ammonium chloride increases acidity by increasing the amount of hydrogen ion concentrations. Ammonium chloride can be used as an expectorant due to its irritative action on the bronchial mucosa. This effect causes the production of respiratory tract fluid which in order facilitates the effective cough. The acid-forming properties of ammonium chloride result from dissociation of the salt to an ammonium cation and a chloride anion. In patients with normal hepatic function, the ammonium cation is converted to urea by the liver and a hydrogen cation is released which reacts with a bicarbonate ion to form water and carbon dioxide. The chloride anion combines with fixed bases in the extracellular fluid, thereby reducing the alkaline reserve of the body. The net result is the displacement of bicarbonate ions by chloride anions. The displacement of bicarbonate by chloride alters the bicarbonate:carbonic acid ratio if the body and acidosis results. The increased chloride concentration in the extracellular fluid produces an increased load to the renal tubules and appreciable amounts of chloride anions escape reabsorption. These anions are excreted along with cations and water. Sodium is the principal cation excreted; however, potassium excretion may also be increased to some degree. By increasing the excretion of both extracellular electrolytes and water, ammonium chloride causes a net loss of extracellular fluid and promotes the mobilization of edema fluid.

Pharmacodynamics

Systemic acidifier. In liver ammonium chloride is converted into urea with the liberation of hydrogen ions ( which lowers the pH) and chloride.

Mechanism of action

Cetirizine, a metabolite of _hydroxyzine_, is an antihistamine drug. Its main effects are achieved through selective inhibition of peripheral H1 receptors. The antihistamine activity of cetirizine has been shown in a variety of animal and human models. _In vivo_ and _ex vivo_ animal models have shown insignificant anticholinergic and antiserotonergic effects. In clinical studies, however, dry mouth was found to be more frequent with cetirizine than with a placebo. In vitro receptor binding studies have demonstrated no detectable affinity of cetirizine for histamine receptors other than the H1 receptors. Studies with radiolabeled cetirizine administration in the rat have demonstrated insignificant penetration into the brain. _Ex vivo_ studies in the mouse have shown that systemically administered cetirizine does not occupy cerebral H1 receptors significantly. Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H1 receptors.

Pharmacodynamics

**General effects and respiratory effects** Cetirizine, the active metabolite of the piperazine H₁-receptor antagonist hydroxyzine, minimizes or eliminates the symptoms of chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis. The clinical efficacy of cetirizine for allergic respiratory diseases has been well established in numerous trials. **Effects on urticaria/anti-inflammatory effects** It has anti-inflammatory properties that may play a role in asthma management. There is evidence that cetirizine improves symptoms of urticaria. Marked clinical inhibition of a wheal and flare response occurs in infants, children as well as adults within 20 minutes of one oral dose and lasts for 24 h. Concomitant use of cetirizine reduces the duration and dose of topical anti-inflammatory formulas used for the treatment of atopic dermatitis.

Mechanism of action

Dextromethorphan is a low-affinity uncompetitive NMDA antagonist and sigma-1 receptor agonist. It is also an antagonist of α3/β4 nicotinic receptors. However, the mechanism by which dextromethorphan's receptor agonism and antagonism translate to a clinical effect is not well understood. Dextromethorphan (DXM) is the dextro isomer of levomethorphan, a semisynthetic morphine derivative. Although structurally similar to other /CNS depressants/, DXM does not act as a mu receptor opioid (eg, morphine, heroin). DXM and its metabolite, dextrorphan, act as potent blockers of the N-methyl-d-aspartate (NMDA) receptor. Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT(1A) receptors, which has been shown to reduce LID. We undertook a study in 6-OHDA rats to determine whether the anti-dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5-HT(1A) agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae-Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM-suppressing effect of amantadine was not affected by the 5-HT(1A) antagonist WAY-100635, but was partially reversed by the NMDA agonist d-cycloserine. Conversely, the AIM-suppressing effect of dextromethorphan was prevented by WAY-100635 but not by d-cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L-DOPA in sensorimotor tests. We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT(1A) agonism. Combined with previous work from our group, our results support the investigation of 5-HT(1A) agonists as pharmacotherapies for LID in PD patients. Dextromethorphan (DM) is a dextrorotatory morphinan and an over-the-counter non-opioid cough suppressant. We have previously shown that DM protects against LPS-induced dopaminergic neurodegeneration through inhibition of microglia activation. Here, we investigated protective effects of DM against endotoxin shock induced by lipopolysaccharide/d-galactosamine (LPS/GalN) in mice and the mechanism underlying its protective effect. Mice were given multiple injections of DM (12.5 mg/kg, s.c.) 30 min before and 2, 4 hr after an injection of LPS/GalN (20 ug/700 mg/kg). DM administration decreased LPS/GalN-induced mortality and hepatotoxicity, as evidenced by increased survival rate, decreased serum alanine aminotransferase activity and improved pathology. Furthermore, DM was also effective when it was given 30 min after LPS/GalN injection. The protection was likely associated with reduced serum and liver tumor necrosis factor alpha (TNF-alpha) levels. DM also attenuated production of superoxide and intracellular reactive oxygen species in Kupffer cells and neutrophils. Real-time RT-PCR analysis revealed that DM administration suppressed the expression of a variety of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intercellular adhesion molecular-1 and interleukin-6. DM also decreased the expression of genes related to cell-death pathways, such as the DNA damage protein genes GADD45 and GADD153. In summary, DM is effective in protecting mice against LPS/GalN-induced hepatotoxicity, and the mechanism is likely through a faster TNF-alpha clearance, and decrease of superoxide production and inflammation and cell-death related components. This study not only extends neuroprotective effect of DM, but also suggests that DM may be a novel compound for the therapeutic intervention for sepsis. /The

Pharmacodynamics

Dextromethorphan is an opioid-like molecule indicated in combination with other medication in the treatment of coughs and pseudobulbar affect. It has a moderate therapeutic window, as intoxication can occur at higher doses. Dextromethorphan has a moderate duration of action. Patients should be counselled regarding the risk of intoxication.